Multiple Sclerosis News Today is providing comprehensive and in-depth coverage of the eighth annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2023 in San Diego, California. The theme of this year’s conference is “MS: Going Viral.”
More than half of the people with relapsing forms of multiple sclerosis (MS) who received Briumvi (ublituximab) in the ULTIMATE clinical trials had no signs of disease activity over the first six…
People infected with the human immunodeficiency virus (HIV) — including HIV-positive individuals who received antiretroviral treatment at some point after infection — are significantly less likely to develop multiple…
Nonwhite populations are underrepresented in research that tests therapies for multiple sclerosis (MS), meaning most available data on a treatment’s effectiveness and safety can’t be generalized to all patients. “The absence of diversity…
Treatment with the experimental oral suspension therapy CNM-Au8 led to improvements in measures of vision, cognitive and motor function, and brain health for people with multiple sclerosis (MS), according to data from…
Activating certain receptors on astrocytes — a type of nerve support cell — may offer a way of treating cognitive problems in multiple sclerosis (MS), according to recent research. MS mouse models genetically…
Limiting calorie intake over two days of each week for three months led to beneficial immune and metabolic changes, as well as improvements in cognitive function, among people with relapsing-remitting multiple sclerosis (RRMS),…
A greater loss of myelin — the protective coating around nerve fibers — in the part of the spinal cord found in the neck was associated with worse disability in people with…
A history of infection with Epstein-Barr virus (EBV) has been shown to be a strong risk factor for developing multiple sclerosis (MS) — but is targeting the virus a viable strategy for…
A certain bacterial species is enriched in the gut of people with secondary progressive multiple sclerosis (SPMS) and may promote neuroinflammation and drive disability progression in these patients, a study found. When isolated…
Psychiatric symptoms such as depression and anxiety are more common among multiple sclerosis (MS) patients in the five years leading up to disease onset than in people from the general population, according to…
Senior science writer Marisa Horak, MS, and science writer Lindsey Shapiro, PhD, talk about how they came to Bionews and Multiple Sclerosis News Today, why conferences like ACTRIMS are important, and the highlights of this year’s forum.
Mitzi Joi Williams, MD, founding medical director of Joi Life Wellness, talks about the documentary “MS in Black and African Americans,” progress that has been made in addressing racial disparities in MS care and research, and what still needs to be done to close the gap.
MS advocate and patient Tyler Campbell discusses the documentary “MS in Black and African Americans,” his MS diagnosis journey, and the importance of taking action to address health inequities among the Black MS community.
Michael Hotchkin, chief development officer of Clene Nanomedicine, explains how experimental therapy CNM-Au8 may help MS patients see improvements in their everyday lives. Full story to come.
Michael Weiss, CEO of TG Therapeutics, talks to Multiple Sclerosis News Today about the pricing of newly approved MS therapy Briumvi (ublituximab) and how they are helping people with MS afford the treatment.
Multiple Sclerosis News Today talks to Mitzi Joi Williams, MD, MS specialist and founding medical director of Joi Life Wellness, about health inequity in Black people with MS and what further work needs to be done to close the gap. Full story and video to come.
MS patient and advocate Tyler Campbell sits down with Multiple Sclerosis News Today to talk about his MS experience and the documentary “MS in Black and African Americans,” which premiered Thursday night at ACTRIMS. Full story and video to come.
Can Do MS Chief Operating Officer Kathy Costello chats with Multiple Sclerosis News Today about the upcoming programs and initiatives they’re most excited about. Full story to come.
Get regular updates to your inbox.
